Developer docs
API playgroundTry for free, no card

Search company profiles

Imagenomix

Full company profile

uuid00ypx8h

Namestring
Imagenomix
Legal namestring
Imagenomix Corp
Websiteurl
imagenomix.ai
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Imagenomix Corp is a privately held AI-driven cancer diagnostics company founded in 2024 as a spin-off from NYU Langone Health. The company develops the IGX Predict AI platform, which uses proprietary computational models to predict cancer-causing genetic mutations from standard Hematoxylin and Eosin (H&E) stained pathology slides within minutes, rather than the weeks required by traditional molecular testing. The technology addresses the problem that 26% of cancer samples are insufficient for traditional testing and claims applicability to 100% of confirmed cancer cases, with positioning that only 20% of US patients and 2% globally currently receive molecular testing.

The product portfolio spans mutation prediction and sample adequacy analysis, whole slide image analysis, custom AI model development for biotech and pharma clients, predictive modeling, multi-omics data analysis, and consulting and telepathology services. An IT Reporting System is under development to deliver comprehensive diagnostic insights to clients. The underlying technology combines computer vision on pathology images with predictive analytics and multimodal integration of multi-omics and clinical data, protected by multiple patent-pending applications credited to co-founder Aris Tsirigos.

Imagenomix operates a B2B sales-led go-to-market targeting three primary customer segments: pathology practices (hospitals and independent laboratories seeking faster, more affordable molecular cancer testing), pharmaceutical companies (clinical trial patient stratification and biomarker identification), and biotechnology firms (drug discovery support and custom AI models). Revenue is generated through subscription-based diagnostic services to pathology practices and professional services fees from pharma/biotech partnerships and custom AI model development, with quote-based enterprise contracts and no publicly disclosed pricing. Distribution is direct enterprise sales, supported by strategic partnerships with Amazon Web Services (cloud infrastructure and Health Equity Initiative, June 2024) and Alterome Therapeutics (clinical trial collaboration, January 2025). The company is headquartered in New York City, reports 1-10 employees, and has disclosed one funding round of $3.2 million led by Modi Ventures.

Short descriptiontext

Imagenomix Corp is an AI-driven cancer diagnostics company whose IGX Predict platform predicts cancer-causing genetic mutations from standard H&E pathology slides in minutes, serving pathology practices, pharmaceutical companies for clinical trial optimization, and biotechnology firms for drug discovery support.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI cancer diagnostics, pathology image analysis, molecular mutation prediction, clinical trial stratification, computational pathology
Industry2 codes
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
AI Cancer Diagnostics
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Diagnostic Services
TypeSubscription Recurring
Description

AI-based analysis of H&E slides and fresh tissue for detection of cancer-causing mutations provided to pathology practices and healthcare organizations.

imagenomix.ai
2Pharmaceutical Partnership Services
TypeProfessional Services
Description

Collaboration with pharmaceutical companies to optimize clinical trials through AI-powered analytics for patient stratification and biomarker identification.

imagenomix.ai
3Custom AI Model Development
TypeProfessional Services
Description

Development of custom AI models tailored to unique client requirements such as mutation detection or drug response prediction for biotech and pharmaceutical clients.

imagenomix.ai
4Consulting and Telepathology Services
TypeProfessional Services
Description

Expert pathologist, data scientist, and AI engineer consulting services to help healthcare organizations integrate AI into pathology workflows.

imagenomix.ai
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1IGX Predict
Description

AI platform that predicts driver mutations for cancer treatment or clinical trials within minutes using computational rather than wet-lab-based techniques.

imagenomix.ai
+1 more record
Core offering1 text field

Imagenomix sells AI-driven cancer diagnostics through its IGX Predict platform, which computationally predicts cancer-causing driver mutations from standard H&E stained pathology slides in minutes. The company also offers custom AI model development, predictive modeling, image analysis, data analysis, and consulting/telepathology services to pharmaceutical, biotechnology, and pathology customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Diagnostic results delivered in minutes vs weeks
+4 more records
Product overview1 text field

Imagenomix offers a unified AI-driven diagnostic platform centered on the IGX Predict system, which provides cancer mutation prediction by analyzing standard H&E pathology slides in minutes rather than weeks. The platform architecture includes core diagnostic services (mutation prediction, image analysis, predictive modeling, data analysis) along with custom AI model development capabilities for pharmaceutical and biotech clients. The company also provides consulting and telepathology services to help healthcare organizations integrate AI into pathology workflows. An IT Reporting System is under development to deliver comprehensive diagnostic insights to clients.

Product and service7 records
1IGX Predict
CategoryAI Cancer Diagnostics Platform
Description

AI platform that predicts cancer-causing driver mutations from standard H&E pathology slides within minutes for cancer treatment decisions and clinical trial enrollment, used by pharmaceutical companies and pathology practices.

2Mutation Prediction and Sample Adequacy Analysis
CategoryDiagnostic Service
Description

Service that predicts targetable mutations and fusions, maps spatial distribution of mutations from pathology tissue, and assesses tissue adequacy for downstream NGS testing, offered to pathology practices and healthcare organizations.

3Custom AI Models
CategoryAI Development Service
Description

Bespoke AI model development service for biotech and pharmaceutical clients requiring tailored mutation detection or drug response prediction capabilities.

4Image Analysis
CategoryDiagnostic Service
Description

AI-powered analysis of whole slide pathology images to identify and classify cancer cells, tumor margins, and disease markers for pathology practices and pharma clients.

5Data Analysis
CategoryAnalytics Service
Description

Analytical service processing large datasets from clinical trials, biobanks, and electronic health records to identify biomarkers, genetic variants, and drug targets for biotech and pharma clients.

6Predictive Modeling
CategoryAnalytics Service
Description

Predictive modeling service that generates disease prognosis, treatment response, and drug efficacy predictions from molecular data and patient characteristics for healthcare and pharma clients.

7Consulting and Telepathology
CategoryConsulting Service
Description

Consulting and telepathology services delivered by expert pathologists, data scientists, and AI engineers to help healthcare organizations and biotech companies integrate AI into pathology workflows.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Groundbreaking partnership to leverage Imagenomix's cutting-edge AI technologies to optimize clinical trial efficiency, improve patient stratification, and accelerate the development of Alterome's targeted cancer therapies. The Imagenomix Predict AI platform will streamline clinical trial timelines through advanced analytics for critical biomarker identification and targeted patient selection.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-06-01
Description

Selected for AWS Health Equity Initiative, a $60 million three-year commitment supporting organizations developing solutions for health equity. Imagenomix will receive computing credits and technical expertise from AWS to further validate the IGX Predict AI Assay for launch with pharma partners to develop cancer mutational cancer screening for targeted therapies globally.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Owkin uses AI on patient data including pathology and omics for drug discovery and clinical trial optimization, with pharma collaborations. Comparable in combining pathology AI with pharma/biotech GTM motion.

TypeDirect peer
Description

PathAI develops AI-powered pathology diagnostics for cancer and other diseases, directly competing with Imagenomix in AI-driven mutation detection from H&E slides and serving both pathology practices and pharma/biotech for clinical trial applications.

3Tempus
TypeBroad incumbent
Description

Tempus is a leading precision medicine company combining genomic sequencing, AI, and clinical data for oncology. Broadly overlaps with Imagenomix on AI-driven molecular profiling and pharma clinical trial services, but operates at much larger scale with NGS infrastructure.

4nference
TypeDirect peer
Description

nference applies AI to biomedical data including pathology, omics, and clinical records to support pharma R&D and clinical development. Comparable in AI-driven biomedical analytics targeting pharma/biotech customers.

TypeDirect peer
Description

Ibex deploys AI for cancer diagnostics in pathology workflows, offering H&E-based detection and decision support tools. Directly comparable as an AI-first pathology company serving clinical labs and healthcare providers.

TypeDirect peer
Description

Paige builds AI applications for pathology, including cancer detection and biomarker prediction from H&E slides, with pharma partnerships for clinical trials. Closely comparable in technology approach and target customer segments.

TypeBroad incumbent
Description

Foundation Medicine (Roche) provides comprehensive genomic profiling assays for oncology, serving pharma for clinical trial enrollment and clinical practice. Overlaps in molecular cancer diagnostics and pharma partnerships, but uses NGS rather than H&E inference.

TypeEmerging player
Description

Proscia provides AI-enabled digital pathology software for cancer diagnosis and research, serving pharma and clinical labs. Comparable as a digital pathology platform company with AI analytics for pharma/biotech customers.

TypeEmerging player
Description

Stratipath uses AI on H&E slides for breast cancer risk stratification and prognostic biomarker prediction. Direct technological overlap as an AI pathology company focused on H&E-based biomarker inference.

TypeDirect peer
Description

ArteraAI develops AI-based multimodal prognostic and predictive biomarkers in oncology, combining pathology images with clinical data. Comparable in using AI on pathology images to predict outcomes and inform treatment decisions in cancer.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Imagenomix

AI Cancer Diagnosticsimagenomix.ai

Imagenomix Corp is an AI-driven cancer diagnostics company whose IGX Predict platform predicts cancer-causing genetic mutations from standard H&E pathology slides in minutes, serving pathology practices, pharmaceutical companies for clinical trial optimization, and biotechnology firms for drug discovery support.

What Imagenomix does

Imagenomix Corp is a privately held AI-driven cancer diagnostics company founded in 2024 as a spin-off from NYU Langone Health. The company develops the IGX Predict AI platform, which uses proprietary computational models to predict cancer-causing genetic mutations from standard Hematoxylin and Eosin (H&E) stained pathology slides within minutes, rather than the weeks required by traditional molecular testing. The technology addresses the problem that 26% of cancer samples are insufficient for traditional testing and claims applicability to 100% of confirmed cancer cases, with positioning that only 20% of US patients and 2% globally currently receive molecular testing.

The product portfolio spans mutation prediction and sample adequacy analysis, whole slide image analysis, custom AI model development for biotech and pharma clients, predictive modeling, multi-omics data analysis, and consulting and telepathology services. An IT Reporting System is under development to deliver comprehensive diagnostic insights to clients. The underlying technology combines computer vision on pathology images with predictive analytics and multimodal integration of multi-omics and clinical data, protected by multiple patent-pending applications credited to co-founder Aris Tsirigos.

Imagenomix operates a B2B sales-led go-to-market targeting three primary customer segments: pathology practices (hospitals and independent laboratories seeking faster, more affordable molecular cancer testing), pharmaceutical companies (clinical trial patient stratification and biomarker identification), and biotechnology firms (drug discovery support and custom AI models). Revenue is generated through subscription-based diagnostic services to pathology practices and professional services fees from pharma/biotech partnerships and custom AI model development, with quote-based enterprise contracts and no publicly disclosed pricing. Distribution is direct enterprise sales, supported by strategic partnerships with Amazon Web Services (cloud infrastructure and Health Equity Initiative, June 2024) and Alterome Therapeutics (clinical trial collaboration, January 2025). The company is headquartered in New York City, reports 1-10 employees, and has disclosed one funding round of $3.2 million led by Modi Ventures.

Imagenomix firmographics

Firmographics
Name
Imagenomix
Legal name
Imagenomix Corp
Website
https://imagenomix.ai
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
Imagenomix Corp is an AI-driven cancer diagnostics company whose IGX Predict platform predicts cancer-causing genetic mutations from standard H&E pathology slides in minutes, serving pathology practices, pharmaceutical companies for clinical trial optimization, and biotechnology firms for drug discovery support.
Ownership category
akta.pro rank

Imagenomix industry classification

Industry
Product category
AI Cancer Diagnostics
NAICS
Medical and Diagnostic Laboratories (62151)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • AI cancer diagnostics
  • Pathology image analysis
  • Molecular mutation prediction
  • Clinical trial stratification
  • Computational pathology

Where Imagenomix is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Imagenomix business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Diagnostic Services: AI-based analysis of H&E slides and fresh tissue for detection of cancer-causing mutations provided to pathology practices and healthcare organizations.
  2. Pharmaceutical Partnership Services: Collaboration with pharmaceutical companies to optimize clinical trials through AI-powered analytics for patient stratification and biomarker identification.
  3. Custom AI Model Development: Development of custom AI models tailored to unique client requirements such as mutation detection or drug response prediction for biotech and pharmaceutical clients.
  4. Consulting and Telepathology Services: Expert pathologist, data scientist, and AI engineer consulting services to help healthcare organizations integrate AI into pathology workflows.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Imagenomix product offering

Product offering

Core offering

Imagenomix sells AI-driven cancer diagnostics through its IGX Predict platform, which computationally predicts cancer-causing driver mutations from standard H&E stained pathology slides in minutes. The company also offers custom AI model development, predictive modeling, image analysis, data analysis, and consulting/telepathology services to pharmaceutical, biotechnology, and pathology customers.

Product overview

Imagenomix offers a unified AI-driven diagnostic platform centered on the IGX Predict system, which provides cancer mutation prediction by analyzing standard H&E pathology slides in minutes rather than weeks. The platform architecture includes core diagnostic services (mutation prediction, image analysis, predictive modeling, data analysis) along with custom AI model development capabilities for pharmaceutical and biotech clients. The company also provides consulting and telepathology services to help healthcare organizations integrate AI into pathology workflows. An IT Reporting System is under development to deliver comprehensive diagnostic insights to clients.

Differentiator

Problem solved

Functional benefit

Brands

  • IGX Predict: AI platform that predicts driver mutations for cancer treatment or clinical trials within minutes using computational rather than wet-lab-based techniques.
  • IGX Predict AI Pharma

Products and services

  • IGX Predict AI platform that predicts cancer-causing driver mutations from standard H&E pathology slides within minutes for cancer treatment decisions and clinical trial enrollment, used by pharmaceutical companies and pathology practices.
  • Mutation Prediction and Sample Adequacy Analysis Service that predicts targetable mutations and fusions, maps spatial distribution of mutations from pathology tissue, and assesses tissue adequacy for downstream NGS testing, offered to pathology practices and healthcare organizations.
  • Custom AI Models Bespoke AI model development service for biotech and pharmaceutical clients requiring tailored mutation detection or drug response prediction capabilities.
  • Image Analysis AI-powered analysis of whole slide pathology images to identify and classify cancer cells, tumor margins, and disease markers for pathology practices and pharma clients.
  • Data Analysis Analytical service processing large datasets from clinical trials, biobanks, and electronic health records to identify biomarkers, genetic variants, and drug targets for biotech and pharma clients.
  • Predictive Modeling Predictive modeling service that generates disease prognosis, treatment response, and drug efficacy predictions from molecular data and patient characteristics for healthcare and pharma clients.
  • Consulting and Telepathology Consulting and telepathology services delivered by expert pathologists, data scientists, and AI engineers to help healthcare organizations and biotech companies integrate AI into pathology workflows.

Quantifiable outcome

  • Diagnostic results delivered in minutes vs weeks
  • +4 more outcomes

Companies that use Imagenomix

Customer profile

Segments3 records

Ideal customer profiles3 records

Imagenomix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Imagenomix partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and core.

  • Alterome Therapeutics Inc.flagshipStrategic or Co-development Partner · 1 January 2025Groundbreaking partnership to leverage Imagenomix's cutting-edge AI technologies to optimize clinical trial efficiency, improve patient stratification, and accelerate the development of Alterome's targeted cancer therapies. The Imagenomix Predict AI platform will streamline clinical trial timelines through advanced analytics for critical biomarker identification and targeted patient selection.
  • Amazon Web Services (AWS)coreTechnology or Integration · 1 June 2024Selected for AWS Health Equity Initiative, a $60 million three-year commitment supporting organizations developing solutions for health equity. Imagenomix will receive computing credits and technical expertise from AWS to further validate the IGX Predict AI Assay for launch with pharma partners to develop cancer mutational cancer screening for targeted therapies globally.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Imagenomix competitors and assessment

Company assessment

Direct peers

  • Owkin: Owkin uses AI on patient data including pathology and omics for drug discovery and clinical trial optimization, with pharma collaborations. Comparable in combining pathology AI with pharma/biotech GTM motion.
  • PathAI: PathAI develops AI-powered pathology diagnostics for cancer and other diseases, directly competing with Imagenomix in AI-driven mutation detection from H&E slides and serving both pathology practices and pharma/biotech for clinical trial applications.
  • nference: nference applies AI to biomedical data including pathology, omics, and clinical records to support pharma R&D and clinical development. Comparable in AI-driven biomedical analytics targeting pharma/biotech customers.
  • Ibex Medical Analytics: Ibex deploys AI for cancer diagnostics in pathology workflows, offering H&E-based detection and decision support tools. Directly comparable as an AI-first pathology company serving clinical labs and healthcare providers.
  • Paige.AI: Paige builds AI applications for pathology, including cancer detection and biomarker prediction from H&E slides, with pharma partnerships for clinical trials. Closely comparable in technology approach and target customer segments.
  • ArteraAI: ArteraAI develops AI-based multimodal prognostic and predictive biomarkers in oncology, combining pathology images with clinical data. Comparable in using AI on pathology images to predict outcomes and inform treatment decisions in cancer.

Broad incumbents

  • Tempus: Tempus is a leading precision medicine company combining genomic sequencing, AI, and clinical data for oncology. Broadly overlaps with Imagenomix on AI-driven molecular profiling and pharma clinical trial services, but operates at much larger scale with NGS infrastructure.
  • Foundation Medicine: Foundation Medicine (Roche) provides comprehensive genomic profiling assays for oncology, serving pharma for clinical trial enrollment and clinical practice. Overlaps in molecular cancer diagnostics and pharma partnerships, but uses NGS rather than H&E inference.

Emerging players

  • Proscia: Proscia provides AI-enabled digital pathology software for cancer diagnosis and research, serving pharma and clinical labs. Comparable as a digital pathology platform company with AI analytics for pharma/biotech customers.
  • Stratipath: Stratipath uses AI on H&E slides for breast cancer risk stratification and prognostic biomarker prediction. Direct technological overlap as an AI pathology company focused on H&E-based biomarker inference.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Imagenomix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Imagenomix leadership team

Management profile

Number of profiles

Profiles6 records

Imagenomix funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Imagenomix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imagenomix

What does Imagenomix do?

Imagenomix sells AI-driven cancer diagnostics through its IGX Predict platform, which computationally predicts cancer-causing driver mutations from standard H&E stained pathology slides in minutes. The company also offers custom AI model development, predictive modeling, image analysis, data analysis, and consulting/telepathology services to pharmaceutical, biotechnology, and pathology customers.

Is Imagenomix a public or private company?

Imagenomix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Imagenomix founded?

Imagenomix was founded in 2024. It employs 1 to 10 people.

Where is Imagenomix based?

Imagenomix is headquartered in New York, United States, in the North America region.

How does Imagenomix make money?

Four revenue lines are on record. Diagnostic Services are the primary driver. The others are pharmaceutical Partnership Services, custom AI Model Development and consulting and Telepathology Services.

Who are Imagenomix's main competitors?

Direct peers on record are Owkin, PathAI, nference, Ibex Medical Analytics, Paige.AI and ArteraAI. Broad incumbents are Tempus and Foundation Medicine. Emerging players are Proscia and Stratipath.

Does Imagenomix have an API?

No public API is recorded for Imagenomix.

What industry is Imagenomix in?

Imagenomix's product category is AI Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 62151 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales